Related Experiment Video
Updated: Jun 27, 2026
How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
Published on: December 14, 2014
Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder
Jeffrey A Bridge1, Boris Birmaher, Satish Iyengar
1Department of Pediatrics, Research Institute at Nationwide Children's Hospital, Center for Innovation in Pediatric Practice, 700 Children's Dr., Columbus, OH 43205, USA. jeff.bridge@nationwidechildrens.org
Insights
Large, multi-site trials in pediatric depression may inflate placebo response rates. Recruiting patients with moderate-to-severe illness is crucial for accurate antidepressant medication studies.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Placebo response rates in pediatric depression trials can impact perceived medication efficacy.
- Understanding factors influencing placebo response is vital for designing effective clinical trials.
Purpose of the Study:
- To investigate the characteristics and predictors of placebo response in pediatric major depressive disorder (MDD) trials.
- To analyze trends in placebo response over time and identify contributing factors.
Main Methods:
- Systematic review and data extraction from 12 randomized controlled trials (RCTs) of antidepressants in pediatric MDD (ages 6-18).
- Analysis of placebo response rates and potential predictors, including number of study sites, baseline illness severity, participant age, and study recency.
Main Results:
- The number of study sites was the strongest predictor of placebo response proportion.
- Lower baseline illness severity was associated with higher placebo response, though this was moderated by the number of sites.
- Younger participants and more recent studies showed higher placebo response rates, linked to multi-site trial trends and publication bias.
Conclusions:
- The increasing trend towards large, multi-site trials may be inflating placebo response in pediatric depression research.
- Future pharmacotherapy studies should focus on recruiting patients with at least moderately severe depression for greater efficiency and informative results.
- Studies need adequate power to explore whether age influences medication and placebo response.
Objective:
The authors examined characteristics and predictors of response to placebo in all available reports of short-term randomized controlled trials of antidepressants for pediatric major depressive disorder.
Method:
Response, defined as a score
Results:
The single best predictor of the proportion of patients taking placebo who responded to treatment was the number of study sites. Baseline severity of illness also emerged as a significant inverse predictor of placebo response, although the strength of this relationship was diminished when number of sites was controlled for. After one large fluoxetine trial was excluded, younger participants showed a higher placebo response rate than older adolescents. Higher placebo response rates in more recent studies were explained by an increasing trend toward large multisite trials and by publication delays and failures to publish some negative trials.
Conclusions:
The recent shift toward large multisite trials of antidepressant medications for pediatric major depression may be contributing to an increasing incidence of response to placebo. Pharmacotherapy studies of pediatric depression that carefully recruit patients with at least moderately severe depression may be more informative and efficient than many trials conducted to date. Such studies should have sufficient power to determine whether age moderates medication and placebo response.
Related Concept Videos
01:54The Placebo Effect
02:07Blind Procedures
01:11Blinding
01:23Antidepressant Drugs: MAOIs and Other Agents